Maravai Lifesciences Holdings, Inc. Class A MRVI 深 沪
等待开盘 08-21 09:30:00 美东时间
8.29
+1.070
+14.82%
华盛通- 最 高8.3781
- 今 开7.44
- 成交量 1314.58万股
- 最 低 7.38
- 昨 收 7.22
- 总市值 21.53亿
- 52周最高 8.3781
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 2.285
- 委 比 72.57%
- 总股本 2.60亿
- 历史最高 63.55
- 量 比 2.88
- 振 幅 13.82%
- 历史最低 1.665
- 每 手 1
- 风险率 1.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | Moderna狂飙177%！美银火速将其目标价翻两番；油气股SOC升近20%
Moderna狂飙177%！美银火速将其目标价翻两番，TEM、BNTX受利好分别升24%、22%；；油气股SOC升近20%，法院裁定其加州管道重启工作将继续进行>>
08-20 16:20
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index gaining over 200 points on Wednesday. Shares of Estee Lauder Companies Inc (NYSE:EL) rose sharply after the company reported better-than-expected fourth-quarter financial results and issued its FY27 sales guidance with its midpoint above estimates. Ad...
08-19 22:08
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5
Wells Fargo analyst Evan Stampler maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and raises the price target from $5.5 to $6.5.
08-07 22:09
The best Quant-rated stocks trading below $10 right now
Seeking Alpha's Quant Rating system has identified a fresh group of sub-$10 stocks that rank among the highest-rated names in its universe, underscoring that low-priced shares can still exhibit strong...
08-03 21:59
Maravai LifeSciences' TriLink BioTechnologies Obtains New Patent From The China National Intellectual Property Administration, Patent Number ZL 2025 1 1246578.X
TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ:MRVI) and global provider of life science reagents and services, has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL 2025 1 1246578.X, covering methods of ...
07-21 04:05
Maravai LifeSciences refinances debt with $180M credit facilities; lowers outstanding borrowings
Maravai LifeSciences (MRVI) announced on Wednesday that its subsidiaries signed a new credit agreement including a $150M term loan facility and a $30M revolving credit facility. The company used the n...
06-03 21:45
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
电话会总结 ｜ Maravai(MRVI)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Maravai业绩会实录，以下是2026年第一季度财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 总营收6,580万美元，同比增长41% - 基础业务营收（剔除COVID相关CleanCap收入）同比增长10% - TriLink业务营收同比增长65%，基础业务增长15% - Cygnus业务营收同比增长略超1% **盈利能力：** - 调整后毛利率65.3%，受益于产品组合优化和成本控制 - 调整后EBITDA为2,030万美元，同比改善超过3,000万美元 - GAAP净亏损（扣除非控制性权益前）640万美元，去年同期为5,
05-10 12:01
Maravai LifeSciences Holdings shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY26 guidance above estimates.
Maravai LifeSciences Holdings shares are trading higher after the company repor...
05-08 05:22
